Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias

Nature Genetics

Volumn 49, Issue 1, 2017, Pages 10-16

  Dunford, Andrew ^a   Weinstock, David M ^a,b   Savova, Virginia ^b,c   Schumacher, Steven E ^a,c   Cleary, John P ^b   Yoda, Akinori ^b   Sullivan, Timothy J ^a   Hess, Julian M ^a   Gimelbrant, Alexander A ^a,b,c   Beroukhim, Rameen ^a,b,c   Lawrence, Michael S ^b   Getz, Gad ^a,b   Lane, Andrew A ^a,b  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATRX GENE; CNKSR2 GENE; CONTROLLED STUDY; DDX3X GENE; FEMALE; GENDER BIAS; HUMAN; KDM5C GENE; KDM6A GENE; LOSS OF FUNCTION MUTATION; MAGEC3 GENE; MALE; NEOPLASM; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; X CHROMOSOME; X CHROMOSOME INACTIVATION; Y CHROMOSOME; GENETICS; MUTATION; SEXISM; STATISTICS AND NUMERICAL DATA; X CHROMOSOMAL INHERITANCE;

CHROMOSOMES, HUMAN, X; FEMALE; GENES, TUMOR SUPPRESSOR; GENES, X-LINKED; HUMANS; MALE; MUTATION; NEOPLASMS; SEXISM; X CHROMOSOME INACTIVATION;

EID: 84997818361     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3726     Document Type: Article

References (58)

1. Edgren, G., Liang, L., Adami, H.O. & Chang, E.T. Enigmatic sex disparities in cancer incidence. Eur. J. Epidemiol. 27, 187-196 (2012).
2. Cook, M.B. et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol. Biomarkers Prev. 18, 1174-1182 (2009).
3. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
4. Van der Meulen, J. et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood 125, 13-21 (2015).
5. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69 (2011).
6. Van Vlierberghe, P. et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat. Genet. 42, 338-342 (2010).
7. van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521-523 (2009).
8. Knudson, A.G. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. USA 90, 10914-10921 (1993).
9. Yang, C. et al. X-chromosome inactivation: molecular mechanisms from the human perspective. Hum. Genet. 130, 175-185 (2011).
10. Berletch, J.B. et al. Escape from X inactivation varies in mouse tissues. PLoS Genet. 11, e1005079 (2015).
11. Berletch, J.B., Yang, F., Xu, J., Carrel, L. & Disteche, C.M. Genes that escape from X inactivation. Hum. Genet. 130, 237-245 (2011).
12. Carrel, L. & Willard, H.F. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434, 400-404 (2005).
13. Johnston, C.M. et al. Large-scale population study of human cell lines indicates that dosage compensation is virtually complete. PLoS Genet. 4, e9 (2008).
14. Talebizadeh, Z., Simon, S.D. & Butler, M.G. X chromosome gene expression in human tissues: male and female comparisons. Genomics 88, 675-681 (2006).
15. Duijf, P.H., Schultz, N. & Benezra, R. Cancer cells preferentially lose small chromosomes. Int. J. Cancer 132, 2316-2326 (2013).
16. Yildirim, E. et al. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell 152, 727-742 (2013).
17. Veiga, L.C., Bérgamo, N.A., Reis, P.P., Kowalski, L.P. & Rogatto, S.R. Loss of Y-chromosome does not correlate with age at onset of head and neck carcinoma: a case-control study. Braz. J. Med. Biol. Res. 45, 172-178 (2012).
18. Zhang, L.J., Shin, E.S., Yu, Z.X. & Li, S.B. Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders. Chin. Med. J. (Engl.) 120, 2002-2005 (2007).
19. Dumanski, J.P. et al. Smoking is associated with mosaic loss of chromosome Y. Science 347, 81-83 (2015).
20. Forsberg, L.A. et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat. Genet. 46, 624-628 (2014).
21. Bellott, D.W. et al. Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators. Nature 508, 494-499 (2014).
22. Cortez, D. et al. Origins and functional evolution of Y chromosomes across mammals. Nature 508, 488-493 (2014).
23. Shpargel, K.B., Sengoku, T., Yokoyama, S. & Magnuson, T. UTX and UTY demonstrate histone demethylase-independent function in mouse embryonic development. PLoS Genet. 8, e1002964 (2012).
24. Welstead, G.G. et al. X-linked H3K27me3 demethylase Utx is required for embryonic development in a sex-specific manner. Proc. Natl. Acad. Sci. USA 109, 13004-13009 (2012).
25. Brat, D.J. et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481-2498 (2015).
26. Pinto, E.M. et al. Genomic landscape of paediatric adrenocortical tumours. Nat. Commun. 6, 6302 (2015).
27. Jiang, L. et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat. Genet. 47, 1061-1066 (2015).
28. Dalgliesh, G.L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
29. Ntziachristos, P. et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513-517 (2014).
30. Dubrow, R. & Darefsky, A.S. Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. BMC Cancer 11, 325 (2011).
31. Wilson Sayres, M.A. & Makova, K.D. Gene survival and death on the human Y chromosome. Mol. Biol. Evol. 30, 781-787 (2013).
32. Bechara, E.G., Sebestyén, E., Bernardis, I., Eyras, E. & Valcárcel, J. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol. Cell 52, 720-733 (2013).
33. Cotton, A.M. et al. Analysis of expressed SNPs identifies variable extents of expression from the human inactive X chromosome. Genome Biol. 14, R122 (2013).
34. Al Nadaf, S. et al. A cross-species comparison of escape from X inactivation in Eutheria: implications for evolution of X chromosome inactivation. Chromosoma 121, 71-78 (2012).
35. Chaligné, R. et al. The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer. Genome Res. 25, 488-503 (2015).
36. Patrat, C. et al. Dynamic changes in paternal X-chromosome activity during imprinted X-chromosome inactivation in mice. Proc. Natl. Acad. Sci. USA 106, 5198-5203 (2009).
37. GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648-660 (2015).
38. Wu, H. et al. Cellular resolution maps of X chromosome inactivation: implications for neural development, function, and disease. Neuron 81, 103-119 (2014).
39. Lawrence, M.S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
40. Vaags, A.K. et al. Absent CNKSR2 causes seizures and intellectual, attention, and language deficits. Ann. Neurol. 76, 758-764 (2014).
41. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
42. Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417-425 (2015).
43. Chaligné, R. & Heard, E. X-chromosome inactivation in development and cancer. FEBS Lett. 588, 2514-2522 (2014).
44. Gibbons, R.J. & Higgs, D.R. Molecular-clinical spectrum of the ATR-X syndrome. Am. J. Med. Genet. 97, 204-212 (2000).
45. Jensen, L.R. et al. Mutations in the JARID1C gene, which is involved in transcriptional regulation and chromatin remodeling, cause X-linked mental retardation. Am. J. Hum. Genet. 76, 227-236 (2005).
46. Miyake, N. et al. MLL2 and KDM6A mutations in patients with Kabuki syndrome. Am. J. Med. Genet. A. 161A, 2234-2243 (2013).
47. Snijders Blok, L. et al. Mutations in DDX3X are a common cause of unexplained intellectual disability with gender-specific effects on Wnt signaling. Am. J. Hum. Genet. 97, 343-352 (2015).
48. Pinto, D. et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466, 368-372 (2010).
49. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-427 (2014).
50. Zack, T.I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134-1140 (2013).
51. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
52. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
53. Siepel, A. et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 15, 1034-1050 (2005).
54. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
55. Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA 104, 20007-20012 (2007).
56. Yoda, A. et al. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nat. Med. 21, 71-75 (2015).
57. Hammerman, P.S. et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 1, 78-89 (2011).
58. Lane, A.A. et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat. Genet. 46, 618-623 (2014).